ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Agendia Responds to “Clinical Insights on MINDACT”
Dear Dr. Febbo, I recently received an email from you, in which you provided your unsolicited “Clinical Insights on MINDACT”. I have been a practicing medical oncologist for nearly 30 years, the last 20 Read More
New England Journal of Medicine Publishes MINDACT Trial Results Proving the Clinical Utility of MammaPrint in Assisting Physicians to Identify Early-Stage Breast Cancer Patients who can Safely Forgo Chemotherapy
46% of patients identified as high risk for recurrence according to clinical-pathological factors as described in the publication, and who therefore would be usual candidates for adjuvant chemotherapy, were reclassified as Low Risk by MammaPrint® Read More
New Data Shows Agendia’s MammaPrint can Prevent Under and Over Treatment of Breast Cancer Patients with an Intermediate/Indeterminate OncotypeDx Recurrence Score
The PRospective study Of MammaPrint in breast cancer patients with an Intermediate recurrence Score (PROMIS) included 840 women at 58 US institutions. 45% of patients with an intermediate/indeterminate Recurrence Score from a 21-gene assay OncotypeDx Read More
Agendia Appoints Dr. Gabriel Hortobagyi as Chairman to their Medical Advisory Board
Company also announces new ASCO data presentation from the prospective PROMIS study assessing the clinical impact of the definitive MammaPrint 70-gene assay results for patients previously classified as indeterminate by the 21-gene assay (OncotypeDx) IRVINE, Read More
